During the past decade, Instituto Nacional de Cancer - INCa; Oncologia conducted 59 clinical trials. In the 10-year time frame, 59 clinical trials started and 40 clinical trials were completed, i.e. on average, 67.8% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 22 clinical trials were completed. i.e. 115.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto Nacional de Cancer - INCa; Oncologia" #1 sponsor was "Hoffmann-La Roche" with 22 trials, followed by "Instituto Nacional de Cancer, Brazil" with 8 trials sponsored, "Pfizer" with 8 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 4 trials sponsored and "Genentech, Inc." with 4 trials sponsored. Other sponsors include 54 different institutions and companies that sponsored additional 49 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto Nacional de Cancer - INCa; Oncologia" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 4 trials as a collaborator, "Hoffmann-La Roche" with 3 trials as a collaborator, "Breast International Group" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator and "GOG Foundation" with 2 trials as a collaborator. Other collaborators include 43 different institutions and companies that were collaborators in the rest 50 trials.

According to Clinical.Site data, the most researched conditions in "Instituto Nacional de Cancer - INCa; Oncologia" are "Breast Cancer" (11 trials), "Metastatic Breast Cancer" (5 trials), "Lung Cancer" (4 trials), "Multiple Myeloma" (4 trials) and "Non-Small Cell Lung Cancer" (4 trials). Many other conditions were trialed in "Instituto Nacional de Cancer - INCa; Oncologia" in a lesser frequency.

Most popular intervention types in "Instituto Nacional de Cancer - INCa; Oncologia" are "Drug" (85 trials), "Biological" (10 trials), "Other" (7 trials), "Procedure" (3 trials) and "Radiation" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Atezolizumab" (11 trials), "Carboplatin" (9 trials), "Paclitaxel" (9 trials) and "Gemcitabine" (8 trials). Other intervention names were less common.

The vast majority of trials in "Instituto Nacional de Cancer - INCa; Oncologia" are 86 trials for "All" genders and 19 trials for "Female" genders.

Currently, there are NaN active trials in "Instituto Nacional de Cancer - INCa; Oncologia". undefined are not yet recruiting, 12 are recruiting, 23 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 46 completed trials in Instituto Nacional de Cancer - INCa; Oncologia, 1 suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto Nacional de Cancer - INCa; Oncologia, 6 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 62 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 3 trials that are defined as “Not Applicable".

Instituto Nacional de Cancer - INCa; Oncologia has several departments that took part in Clinical trials: "MS INCA HC I Hospital do Cancer I" - 4 trials, "Instituto Nacional de Cancer Jose Alencar Gomes da Silva - INCA" - 3 trials, "Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA" - 2 trials, "Hospital do Cancer III" - 6 trials